Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Open in API
Filings indexed 950 across all filing types
Latest filing 2022-05-26 Regulatory Filings
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The text mentions a press release about poster presentations at a medical program and includes an exhibit of the press release. There are no financial statements or detailed financial data presented. The document is short (4104 characters) and primarily serves as a disclosure of an event and a press release, not a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-05-26 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-16 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions that the company issued a press release announcing its financial results for the first quarter ended March 31, 2022, and that the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 3790 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, if a document is short and states that a report or press release is furnished or attached, it should be classified as a Regulatory Filing (RNS) rather than an Interim Report (IR) or Earnings Release (ER). Therefore, this document is best classified as a Regulatory Filing (RNS).
2022-05-16 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text describes the execution of a Letter Amendment to an At The Market Offering Agreement and includes exhibits such as the amendment letter and legal opinion. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is primarily an announcement of a material definitive agreement and related legal opinions. This fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous filings that do not fit other specific categories. The document length is 3810 characters, which is relatively short and consistent with an 8-K filing announcement rather than a full report.
2022-05-02 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a shelf registration statement for an At The Market Offering of common stock. It details the terms of the offering, use of proceeds, risk factors, plan of distribution, and other related information. This type of document is a capital raising disclosure describing financing activities and terms of share issuance. It is not a financial report, earnings release, or management discussion. It is a detailed update on capital raising and share issuance under a registered offering. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high given the clear identification of the document as a prospectus supplement for a stock offering.
2022-05-02 English
Regulatory Filings 2022
Regulatory Filings
2022-05-02 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.